Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Medigene AG

Start price
Target price
Perf. (%)
€4.63
€6.00
0.000%

Could be worthwhile Investment >10% per year
Genmark Diagnostics

Start price
Target price
Perf. (%)
€11.20
€12.00
-3.571%

Could be worthwhile Investment >10% per year
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€6.70
€8.00
-1.493%

Could be worthwhile Investment >10% per year
Cutera Inc.

Start price
Target price
Perf. (%)
€16.40
€18.00
1.220%

Could be worthwhile Investment >10% per year
CHF Solutions Inc

Start price
Target price
Perf. (%)
€0.19
€0.000
-

Could be very worthwhile Investment >20% year
Trillium Therapeutics

Start price
Target price
Perf. (%)
€8.28
-
57.005%

Could be very worthwhile Investment >20% year
Cti Biopharma Corp

Start price
Target price
Perf. (%)
€0.84
-
8.946%

Risky Investment
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€4.94
-
51.822%

Risky Investment
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€128.00
€135.00
0.781%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Higher risks for its business
Novavax Inc.

Start price
Target price
Perf. (%)
€80.99
-
20.348%

Could be very worthwhile Investment >20% year
Cocrystal Pharma Inc.

Start price
Target price
Perf. (%)
€0.73
-
12.414%

Could be very worthwhile Investment >20% year
PerkinElmer Inc.

Start price
Target price
Perf. (%)
€104.00
-
-2.885%

Growths faster than the competition
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Grifols S.A.

Start price
Target price
Perf. (%)
€22.77
€28.00
5.665%

Could be worthwhile Investment >10% per year
Stratec SE

Start price
Target price
Perf. (%)
€105.60
€95.00
4.735%

Probably not worthwhile Investment
Revenue decline/stagnation expected
High valuation
Very low/no dividend yield expected
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€55.32
€50.00
0.838%

Known brand
Probably not worthwhile Investment
Significant cyclical dependencies
Revenue decline/stagnation expected
Amgen Inc.

Start price
Target price
Perf. (%)
€207.40
€225.00
0.964%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Seres Therapeutics Inc

Start price
Target price
Perf. (%)
€21.00
€12.00
8.571%

Probably not worthwhile Investment
Kazia Therapeutics ADR

Start price
Target price
Perf. (%)
€6.50
-
-13.846%

Probably not worthwhile Investment
Motus GI Holdings Inc

Start price
Target price
Perf. (%)
€0.84
-
2.994%

Could be very worthwhile Investment >20% year
iBio Inc.

Start price
Target price
Perf. (%)
€1.47
-
34.014%

Risky Investment
AstraZeneca plc

Start price
Target price
Perf. (%)
€95.39
€105.50
-0.094%

Future proof or reliable business model
Small cyclical dependencies
Known brand
Organovo Holdings Inc.

Start price
Target price
Perf. (%)
€6.56
€0.000
0.000%

Bayer AG

Start price
Target price
Perf. (%)
€57.13
€80.00
-0.893%

Could be worthwhile Investment >10% per year
Innovative
Medium risks for its business
Known brand
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€58.10
-
-3.987%

Could be worthwhile Investment >10% per year
Capable Management
Innovative
Market Leader or Top 3
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€321.10
-
-6.883%

EBIT growth >5% per year expected
Very low/no dividend yield expected